Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | QDPR | P09417 | 1/20 | 0.35 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065840 | 0.78 | ALDH1A1 (0.38) | NOTUMSMN1; SMN2CYP3A4CYP1A2 | |
| SCHEMBL3590067 | 0.76 | RAB9A (0.38) | MAPTLMNANOTUMSMN1; SMN2TP53 | |
| SCHEMBL28159708 | 0.76 | ESR1 (0.46) | MAPTLMNASMN1; SMN2TP53PKM | |
| SCHEMBL2764416 | 0.76 | TDP1 (0.38) | LMNANOTUMSMN1; SMN2PKMKDM4E | |
| SCHEMBL3516703 | 0.76 | CYP1A2 (0.39) | LMNANOTUMSMN1; SMN2TP53KDM4E | |
| SCHEMBL1435891 | 0.74 | CYP2A6 (0.54) | MAPTLMNAKIF11SMN1; SMN2TP53 | |
| SCHEMBL27459678 | 0.73 | MMP3 (0.45) | NOTUMKIF11GAA | |
| SCHEMBL9465257 | 0.71 | CYP2A6 (0.41) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15716024 | 0.70 | APP (0.48) | MAPTSMN1; SMN2TP53PKMCYP3A4 | |
| SCHEMBL135626 | 0.69 | MAPT (0.92) | MAPTLMNANOTUMKIF11SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4399206-A1 | PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES | Redona Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| CN-118201914-A | 4-Oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives as PAPD5 and/or PAPD7 inhibitors | 雷多纳治疗公司 | 2024-06-14 | — | — | CN | claimed |
| WO-2023039089-A1 | PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES | TWENTYEIGHT-SEVEN, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| CN-1894235-A | N-(4-carbamimidoyl-benzyl) -2-alkoxy-2-heterocyclyl acetamides as inhibitors of the formation of coagulation factors xa, ixa and thrombin induced by factor viia | HOFFMANN LA ROCHE (CH) | 2007-01-10 | — | — | CN | claimed |
| EP-1706396-A1 | N-(4-CARBAMIMIDOYL-BENZYL)-2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA | F.HOFFMANN-LA ROCHE AG (CH) | 2006-10-04 | — | — | EP | claimed |
| US-7056932-B2 | Heterocyclyl substituted 1-alkoxy acetic acid amides | HOFFMAN-LA ROCHE INC. (US) | 2006-06-06 | — | — | US | claimed |
| WO-2005058868-A1 | N-(4-CARBAMIMIDOYL-BENZYL) -2-ALKOXY-2-HETEROCYCLYL ACETAMIDES AS INHIBITORS OF THE FORMATION OF COAGULATION FACTORS XA, IXA AND THROMBIN INDUCED BY FACTOR VIIA | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-30 | — | — | WO | claimed |
| US-20050137168-A1 | Heterocyclyl substituted 1-alkoxy acetic acid amides | HOFFMANN-LA ROCHE INC. | 2005-06-23 | — | — | US | claimed |
| EP-4399206-A1 | PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES | Redona Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118201914-A | 4-Oxo-1, 4-dihydroquinoline-3-carboxylic acid derivatives as PAPD5 and/or PAPD7 inhibitors | 雷多纳治疗公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023039089-A1 | PAPD5 AND/OR PAPD7 INHIBITING 4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID DERIVATIVES | TWENTYEIGHT-SEVEN, INC. (US) | 2023-03-16 | — | — | WO | disclosed |
| EP-2245038-B1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2018-11-07 | — | — | EP | disclosed |
| CN-103142632-B | The Macrolide being used for the treatment of disease mediated by suppressing PDE | BASLIER PHARMACEUTICAL AG (CH) | 2016-01-20 | — | — | CN | disclosed |
| US-9073910-B2 | 5-aryl isoxazolines for controlling invertebrate pests | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2015-07-07 | — | — | US | disclosed |
| EP-1478653-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2004-11-24 | — | — | EP | disclosed |
| US-6740642-B2 | ACTIVE AGAINST GRAM POSITIVE PATHOGENS SUCH AS STAPHYLOCOCCUS AUREUS, STREPTOCOCCUS PNEUMONIAE, GRAM NEGATIVE STRAINS SUCH AS HAEMOPHILUS INFLUENZAE; IMPROVED STABILITY | BASILEA PARMACEUTICA AG (CH) | 2004-05-25 | — | — | US | disclosed |
| CN-1464880-A | New macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-12-31 | — | — | CN | disclosed |
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| WO-2003072588-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2003-09-04 | — | — | WO | disclosed |
| US-5246914-A | Fungicides and plant growth regulators | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137168-A1 | Heterocyclyl substituted 1-alkoxy acetic acid amides | F12, TFPI, F11 | MAPT 4778/4885LMNA 2335/4885NOTUM 1580/4885 |
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | MAPT 4858/4885LMNA 333/4885NOTUM 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.